Hoppa till innehållet

OMXSPI+1,18%

S&P 500+0,30%

FTSE 100+0,05%

DAX+0,33%

NIKKEI+0,73%
Redeye: Vitrolife - Industrious and purposeful consolidation

Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitrolife. The new 5-year target is >10% organic growth target is perhaps the most interesting. Our take is that Vitrolife has established a sufficient footprint where future opportunities are more related to regional commercial opportunities, innovation combined with complementary acquisitions supporting the vertical integration strategy. Our updated view is a base case valuation of SEK 235 (220) and a Bull Case of SEK 375 (330), and a Bear Case of SEK 95 (95).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vitrolife - Industrious and purposeful consolidation

Source:MFN
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill du bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

spara
1180kr
Prenumerera